Navigation Links
Cadence Pharmaceuticals' CEO Ted Schroeder To Present at the Oppenheimer 20th Annual Healthcare Conference in New York City on November 4, 2009
Date:10/28/2009

SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's corporate overview on Wednesday, November 4, 2009 at 2:45pm Eastern Time (11:45am Pacific Time) during the Oppenheimer 20th Annual Healthcare Conference at the Waldorf Astoria Hotel in New York City.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 90 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company is currently developing Acetavance(TM) (intravenous acetaminophen), its investigational product candidate for the treatment of acute pain and fever. For more information about Cadence's pipeline, visit www.cadencepharm.com.

Cadence(TM) and Acetavance(TM) are trademarks of Cadence Pharmaceuticals, Inc.

    Contacts:   William R. LaRue
                SVP, CFO
                Cadence Pharmaceuticals, Inc.
                858-436-1400

SOURCE Cadence Pharmaceuticals, Inc.


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
4. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
5. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
6. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
7. Cadence Pharmaceuticals to Webcast October 7th Analyst Day
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27, 2009
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... , Pa. and KALAMAZOO, Mich. , ... Allentown, Penn. , and OptiMed Specialty Pharmacy of ... business partnership to offer a strategic hub service that ... Healthcare,s highly sought-after personal spirometer, Spiro PD 2.0, and ... A spirometer is a medical device used to ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
(Date:9/7/2017)... , Sept. 7, 2017  For nearly two decades, New Life Agency ... Assisted Reproduction Insurance industry. Today, New Life Agency announces a powerful three-way ... ... ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
Breaking Medicine Technology:
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... asked at a gathering of executive marketers this week about the value of ... , "Everything that has happened in business has brought us to the ...
(Date:9/20/2017)... ... September 20, 2017 , ... “They Sang At Her Funeral”: a tale of ... revealing the skeletons in their closets. “They Sang At Her Funeral” is the creation ... young and married with five children and twelve grandchildren. Before becoming a writer, Annalise ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, a leading ... Denise Flannery, to its strategic advisory and client development team. , In ... with clients across different industries to develop and implement market-justified strategies, modernize and ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... McFarland has joined its executive team as the President of its HealthBI ... care management systems and contact centers. , “Scott is a utility player ...
(Date:9/19/2017)... ... September 19, 2017 , ... MelaKids, a Laredo-based company, has ... filter. When we’re born, Nature gives us a full supply of melanin – ... we continuously lose this natural glare-reducing pigment; however, around the age of thirty, we ...
Breaking Medicine News(10 mins):